hubergroup India expands its support for rural healthcare

hubergroup’s two newly added medical vans are dedicated to dental and eye care

Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study

The data from this study show that MM-II has the potential to provide durable pain relief for our patients

PM chairs high-level meeting to asses situation of Covid-19 & Influenza

PM emphasises the need to enhance lab surveillance & testing of all Severe Acute Respiratory Illness (SARI) cases & ramp up genome sequencing

OPPI launches ‘Bharat Ke Liye’ to reinforce commitment to improve health outcomes

This initiative encapsulates the essence of OPPI’s commitment towards enabling a healthier India

Zydus receives final and tentative approval from USFDA for Tofacitinib Tablets

Tofacitinib Tablets, 5 mg and 10 mg had annual sales of US $900 million in the United States (IQVIA MAT December 2022)

Zydus granted Orphan Drug Designation by USFDA for ZYIL1

ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates

CTSI appoints Harish Trivedi as CEO, South Asia

Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing

All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking

AI platforms market for healthcare industry to reach $4.3 billion in 2024: GlobalData

Various healthcare companies are already implementing high-tech solutions into existing healthcare systems.

Phase 3 data show Deuruxolitinib significantly improve scalp hair regrowth in Alopecia Areata

The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022